Skip to main content
. Author manuscript; available in PMC: 2019 Jun 17.
Published in final edited form as: Biol Blood Marrow Transplant. 2017 Nov 8;24(2):359–365. doi: 10.1016/j.bbmt.2017.10.040

Figure 4. Overall Survival and Progression Free Survival (PFS) and GVHD/Progression Free Survival (GPFS) for all lymphoid malignancy patients.

Figure 4.

Three-year GPFS, PFS and OS was 53% (95% CI 36–68), 62% (95% CI 44–75) and 65% (95% CI 48–78). (N=42)